全文获取类型
收费全文 | 545篇 |
免费 | 40篇 |
国内免费 | 39篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 17篇 |
妇产科学 | 7篇 |
基础医学 | 50篇 |
口腔科学 | 14篇 |
临床医学 | 101篇 |
内科学 | 136篇 |
皮肤病学 | 8篇 |
神经病学 | 34篇 |
特种医学 | 92篇 |
外科学 | 34篇 |
综合类 | 16篇 |
预防医学 | 26篇 |
眼科学 | 4篇 |
药学 | 46篇 |
中国医学 | 9篇 |
肿瘤学 | 27篇 |
出版年
2021年 | 6篇 |
2020年 | 5篇 |
2019年 | 7篇 |
2018年 | 11篇 |
2017年 | 5篇 |
2016年 | 7篇 |
2015年 | 14篇 |
2014年 | 16篇 |
2013年 | 26篇 |
2012年 | 19篇 |
2011年 | 20篇 |
2010年 | 26篇 |
2009年 | 23篇 |
2008年 | 19篇 |
2007年 | 40篇 |
2006年 | 16篇 |
2005年 | 17篇 |
2004年 | 7篇 |
2003年 | 5篇 |
2002年 | 5篇 |
2001年 | 9篇 |
1999年 | 8篇 |
1998年 | 23篇 |
1997年 | 19篇 |
1996年 | 17篇 |
1995年 | 11篇 |
1994年 | 16篇 |
1993年 | 15篇 |
1992年 | 6篇 |
1991年 | 11篇 |
1990年 | 5篇 |
1989年 | 10篇 |
1988年 | 14篇 |
1987年 | 7篇 |
1986年 | 13篇 |
1985年 | 8篇 |
1984年 | 7篇 |
1983年 | 13篇 |
1982年 | 5篇 |
1980年 | 9篇 |
1979年 | 6篇 |
1978年 | 5篇 |
1976年 | 8篇 |
1945年 | 4篇 |
1944年 | 4篇 |
1841年 | 7篇 |
1840年 | 13篇 |
1838年 | 8篇 |
1833年 | 3篇 |
1830年 | 5篇 |
排序方式: 共有624条查询结果,搜索用时 323 毫秒
101.
102.
The classification of Bright''s Disease has claimed much attcntion
during the present century. Some clinicians content themselves with
the simple division into acute and chronic nephritis. This seems
hardly adequate when one considers the varying types of the disease
which one encounters. 相似文献
103.
104.
Preparation and distribution of 5-fluorouracil 125I sodium alginate-bovine serum albumin nanoparticles 总被引:1,自引:0,他引:1
NTRODUCTIONNanoparticle(NP)isancoloidaldispersionsystem,withdiametersrangingfrom10nmto1000nm.Theparticlesexistmainlyintheorga... 相似文献
105.
胃肠胰胰岛淀粉样多肽的定位和表达 总被引:5,自引:3,他引:2
胰岛淀粉样多肽(islet armyloid polypeptide,IAPP)是1986年瑞典学者Westermarket al[1,2 ]从胰岛素瘤患者的瘤组织,糖尿病猫及Ⅱ型糖尿病患者胰岛淀粉样沉积物中分离出来的一种多肽,几乎在同时,英国生物化学家Cooper et al[3,4]也从Ⅱ型糖尿病患者的胰岛淀粉样沉积物中分离出该肽.IAPP又称为amylin.对IAPP的分子结构、基因表达和生理作用等已有许多报道[5].近年来,在IAPP定位、表达及胃肠胰IAPP免疫反应(immunoreactive,IR)细胞定位、发生、发育方面的研究报道,为探讨IAPP的生理作用及疾病状态下的改变,提供了形态学依据,现综述如下. 相似文献
106.
Xavier Bonfill María Jos Martinez-Zapata Robin WM Vernooij María Jos Snchez María Morales-Surez-Varela Jos Ignacio Emparanza Montse Ferrer Jos Ignacio Pijoan Joan Palou Eva Madrid Víctor Abraira Javier Zamora 《Medicine》2021,100(47)
The therapeutic approach is crucial to prostate cancer prognosis. We describe treatments and outcomes for a Spanish cohort of patients with prostate cancer during the first 12 months after diagnosis and identify the factors that influenced the treatment they received.This multicenter prospective cohort study included patients with prostate cancer followed up for 12 months after diagnosis. Treatment was stratified by factors such as hospital, age group (<70 and ≥70 years), and D’Amico cancer risk classification. The outcomes were Eastern Cooperative Oncology Group (ECOG) performance status, adverse events (AEs), and mortality. The patient characteristics associated with the different treatment modalities were analyzed using multivariate logistic regression.We included 470 men from 7 Spanish tertiary hospitals (mean (standard deviation) age 67.8 (7.6) years), 373 (79.4%) of which received treatment (alone or in combination) as follows: surgery (n = 163; 34.7%); radiotherapy (RT) (n = 149; 31.7%); and hormone therapy (HT) (n = 142; 30.2%). The remaining patients (n = 97) were allocated to no treatment, that is, watchful waiting (14.0%) or active surveillance (5.7%). HT was the most frequently administered treatment during follow-up and RT plus HT was the most common therapeutic combination. Surgery was more frequent in patients aged <70, with lower histologic tumor grades, Gleason scores <7, and lower prostate-specific antigen levels; while RT was more frequent in patients aged ≥70 with histologic tumor grade 4, and higher ECOG scores. HT was more frequent in patients aged ≥70, with histologic tumor grades 3 to 4, Gleason score ≥8, ECOG ≥1, and higher prostate-specific antigen levels. The number of fully active patients (ECOG score 0) decreased significantly during follow-up, from 75.3% at diagnosis to 65.1% at 12 months (P < .001); 230 (48.9%) patients had at least 1 AE, and 12 (2.6%) patients died.Surgery or RT were the main curative options. A fifth of the patients received no treatment. Palliative HT was more frequently administered to older patients with higher tumor grades and higher Gleason scores. Close to half of the patients experienced an AE related to their treatment. 相似文献
107.
108.
109.
Judith de Vos-Geelen Sandra ME Geurts Margreet van Putten Liselot BJ Valkenburg-van Iersel Heike I Grabsch Nadia Haj Mohammad Frank JP Hoebers Chantal V Hoge Paul M Jeene Evelien JM de Jong Hanneke WM van Laarhoven Tom Rozema Marije Slingerland Vivianne CG Tjan-Heijnen Grard AP Nieuwenhuijzen Valery EPP Lemmens 《World journal of gastroenterology : WJG》2019,25(47):6835-6846
BACKGROUND The management of proximal esophageal cancer differs from that of tumors located in the mid and lower part of the esophagus due to the close vicinity of vital structures. Non-surgical treatment options like radiotherapy and definitive chemoradiation(CRT) have been implemented. The trends in(non-)surgical treatment and its impact on overall survival(OS) in patients with proximal esophageal cancer are unclear, related to its rare disease status. To optimize treatment strategies and counseling of patients with proximal esophageal cancer,it is therefore essential to gain more insight through real-life studies.AIM To establish trends in treatment and OS in patients with proximal esophageal cancer.METHODS In this population-based study, patients with proximal esophageal cancer diagnosed between 1989 and 2014 were identified in the Netherlands Cancer Registry. The proximal esophagus consists of the cervical esophagus and the upper thoracic section, extending to 24 cm from the incisors. Trends in radiotherapy, chemotherapy, and surgery, and OS were assessed. Analyses were stratified by presence of distant metastasis. Multivariable Cox proportional hazards regression analyses was performed to assess the effect of period of diagnosis on OS, adjusted for patient, tumor, and treatment characteristics.RESULTS In total, 2783 patients were included. Over the study period, the use of radiotherapy, resection, and CRT in non-metastatic disease changed from 53%,23%, and 1% in 1989-1994 to 21%, 9%, and 49% in 2010-2014, respectively. In metastatic disease, the use of chemotherapy and radiotherapy increased over time. Median OS of the total population increased from 7.3 mo [95% confidence interval(CI): 6.4-8.1] in 1989-1994 to 9.5 mo(95%CI: 8.1-10.8) in 2010-2014(logrank P 0.001). In non-metastatic disease, 5-year OS rates improved from 5%(95%CI: 3%-7%) in 1989-1994 to 13%(95%CI: 9%-17%) in 2010-2014(logrank P 0.001). Multivariable regression analysis demonstrated a significant treatment effect over time on survival. In metastatic disease, median OS was 3.8 mo(95%CI:2.5-5.1) in 1989-1994, and 5.1 mo(95%CI: 4.3-5.9) in 2010-2014(logrank P = 0.26).CONCLUSION OS significantly improved in non-metastatic proximal esophageal cancer, likely to be associated with an increased use of CRT. Patterns in metastatic disease did not change significantly over time. 相似文献
110.
T Ibrahim B Bloch CN Esler KR Abrams WM Harper 《Annals of the Royal College of Surgeons of England》2010,92(3):231-235